Biomarkers of sepsis in burn injury: an update

Abstract

Sepsis, a dysregulated response to infection, is a leading cause of death after burn injury. Changes in the immune response as well as the loss of the skin, the primary barrier to infection, contribute to the increased risk for infection and sepsis in burn patients. This higher risk is further compounded by the development of the systemic inflammatory response and hypermetabolic state, which limit the utility of commonly used infection markers. As such, the development of sepsis biomarkers after burn injury is an imperative. A sepsis biomarker would facilitate earlier diagnosis and treatment of sepsis, thus decreasing length of stay, morbidity, and mortality after burn injury. Numerous different biomarkers, ranging from acute phase reactants, cytokines, and inflammatory markers to omics analyses and extracellular vesicles have been assessed as potential biomarkers in burn sepsis. To date no single biomarker has proven useful as the sole indicator for sepsis. The future of burn sepsis biomarkers will likely require a panel of biomarkers from all categories. The purpose of this review article is to list the various biomarkers that have been studied in burn sepsis and describe their clinical utility and future use in patients with burn injury.

Keywords

Sepsis / Burn injury / Biomarkers / Infection / Diagnosis

References

[1] Moins-Teisserenc H, Cordeiro DJ, Audigier V, Ressaire Q, Benyamina M, Lambert J, et al. Severe altered immune status after burn injury is associated with bacterial infection and septic shock. Front Immunol. 2021; 12: 586195. https://doi.org/10.3389/fimmu.2021.586195.

[2] Finnerty CC, Herndon DN, Chinkes DL, Jeschke MG. Serum cytokine differences IN severely burned CHILDREN with and without sepsis. Shock. 2007; 27: 4-9. https://doi.org/10.1097/01.shk.0000235138.20775.36.

[3] Girardot T, Rimmelé T, Venet F, Monneret G. Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis. 2017; 22: 295-305. https://doi.org/10.1007/s10495-016-1325-3.

[4] Williams FN, Herndon DN, Hawkins HK, Lee JO, Cox RA, Kulp GA, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care Lond Engl. 2009; 13: R183. https://doi.org/10.1186/cc8170.

[5] Lavrentieva A, Kontakiotis T, Lazaridis L, Tsotsolis N, Koumis J, Kyriazis G, et al. Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis? Burns J Int Soc Burn Inj. 2007; 33: 189-94. https://doi.org/10.1016/j.burns.2006.07.001.

[6] Zhang P, Zou B, Liou Y-C, Huang C. The pathogenesis and diagnosis of sepsis post burn injury. Burns Trauma. 2021; 9: tkaa047. https://doi.org/10.1093/burnst/tkaa047.

[7] Dupuy A-M, Philippart F, Péan Y, Lasocki S, Charles P-E, Chalumeau M, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review: I-currently available biomarkers for clinical use in acute infections. Ann Intensive Care. 2013; 3: 22. https://doi.org/10.1186/2110-5820-3-22.

[8] Gendrel D, Assicot M, Raymond J, Moulin F, Francoual C, Badoual J, et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr. 1996; 128: 570-3. https://doi.org/10.1016/S0022-3476(96)70374-8.

[9] Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13: 426-35. https://doi.org/10.1016/S1473-3099(12)70323-7.

[10] Long B, Koyfman A. Ready for prime time? Biomarkers in sepsis. Emerg Med Clin North Am. 2017; 35: 109-22. https://doi.org/10.1016/j.emc.2016.09.004.

[11] Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000; 26 Suppl 2: S148-52. https://doi.org/10.1007/s001340051134.

[12] Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med. 1999; 27: 2172-6. https://doi.org/10.1097/00003246-199910000-00016.

[13] Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004; 39: 206-17. https://doi.org/10.1086/421997.

[14] Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret G-Y. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006; 34: 1996-2003. https://doi.org/10.1097/01.CCM.0000226413.54364.36.

[15] Li AT, Moussa A, Gus E, Paul E, Yii E, Romero L, et al. Biomarkers for the early diagnosis of sepsis in burns: systematic review and meta-analysis. Ann Surg. 2022; 275: 654-62. https://doi.org/10.1097/SLA.0000000000005198.

[16] Cabral L, Afreixo V, Almeida L, Paiva JA. The use of Procalcitonin (PCT) for diagnosis of sepsis in burn patients: a meta-analysis. PLoS One. 2016; 11:e0168475. https://doi.org/10.1371/journal.pone.0168475.

[17] Nunez Lopez O, Cambiaso-Daniel J, Branski LK, Norbury WB, Herndon DN. Predicting and managing sepsis in burn patients: current perspectives. Ther Clin Risk Manag. 2017;Volume 13: 1107-17. https://doi.org/10.2147/TCRM.S119938.

[18] Muñoz B, Suárez-Sánchez R, Hernández-Hernández O, Franco-Cendejas R, Cortés H, Magaña JJ. From traditional biochemical signals to molecular markers for detection of sepsis after burn injuries. Burns J Int Soc Burn Inj. 2019; 45: 16-31. https://doi.org/10.1016/j.burns.2018.04.016.

[19] Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012; 25: 609-34. https://doi.org/10.1128/CMR.00016-12.

[20] Jeschke MG, Finnerty CC, Kulp GA, Kraft R, Herndon DN. Can we use C-reactive protein levels to predict severe infection or sepsis in severely burned patients? Int J Burns Trauma. 2013; 3: 137-43.

[21] Song J, Ozhathil DK, El Ayadi A, Golovko G, Wolf SE. C-reactive protein elevation is associated with increased morbidity and mortality in elderly burned patients. Burns J Int Soc Burn Inj. 2023; 49: 806-12. https://doi.org/10.1016/j.burns.2022.05.008.

[22] Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PLoS One. 2013; 8: e69232. https://doi.org/10.1371/journal.pone.0069232.

[23] Zhang H, Wang X, Zhang Q, Xia Y, Liu D. Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatr. 2017; 17: 173. https://doi.org/10.1186/s12877-017-0566-5.

[24] Bhandari B, Cunningham J. The role of brain natriuretic peptide as a prognostic marker for sepsis. Cureus. 2020; 12: e8954. https://doi.org/10.7759/cureus.8954.

[25] Choi Y, Lee JH. Clinical usefulness of NT-proBNP as a prognostic factor for septic shock patients presenting to the emergency department. Sci Rep. 2024; 14: 10999. https://doi.org/10.1038/s41598-024-61888-5.

[26] Paratz JD, Lipman J, Boots RJ, Muller MJ, Paterson DL. A new marker of sepsis post burn injury?∗. Crit Care Med. 2014; 42: 2029-36. https://doi.org/10.1097/CCM.0000000000000400.

[27] Zhou B, Zhu J, Mao Z, Liu L. Roles of Procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting catheter-related bloodstream infection in severe burn injury patients. Dis Markers. 2018; 2018: 1-6. https://doi.org/10.1155/2018/5607932.

[28] Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, et al. Role of cytokines as a double-edged sword in sepsis. Vivo Athens Greece. 2013; 27: 669-84.

[29] Vandijck DM, Brusselaers N, Blot SI. Inflammatory markers in patients with severe burn injury: what is the best indicator of sepsis? Burns J Int Soc Burn Inj. 2007;33:939author reply 941-942-40. https://doi.org/10.1016/j.burns.2007.02.003.

[30] Surbatovic M, Veljovic M, Jevdjic J, Popovic N, Djordjevic D, Radakovic S. Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma. Mediat Inflamm. 2013; 2013: 1-11. https://doi.org/10.1155/2013/362793.

[31] Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20: 87-103. https://doi.org/10.1615/CritRevEukarGeneExpr.v20.i2.10.

[32] Yeh FL, Lin WL, Shen HD, Fang RH. Changes in serum tumour necrosis factor-alpha in burned patients. Burns J Int Soc Burn Inj. 1997; 23: 6-10. https://doi.org/10.1016/S0305-4179(96)00071-X.

[33] Schlüter B, König B, Bergmann U, Müller FE, König W. Interleukin 6-a potential mediator of lethal sepsis after major thermal trauma: evidence for increased IL-6 production by peripheral blood mononuclear cells. J Trauma. 1991; 31: 1663-70. https://doi.org/10.1097/00005373-199112000-00017.

[34] Pileri D, Accardo Palombo A, D’Amelio L, D’Arpa N, Amato G, Masellis A, et al. Concentrations of cytokines IL-6 and IL-10 in plasma of burn patients: their relationship to sepsis and outcome. Ann Burns Fire Disasters. 2008; 21: 182-5.

[35] Ma L, Zhang H, Yin Y, Guo W, Ma Y, Wang Y, et al. Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome. Cytokine. 2016; 88: 126-35. https://doi.org/10.1016/j.cyto.2016.08.033.

[36] Yeh FL, Lin WL, Shen HD, Fang RH. Changes in levels of serum IL-8 in burned patients. Burns. 1997; 23: 555-9. https://doi.org/10.1016/S0305-4179(97)00071-5.

[37] Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive value of IL-8 for sepsis and severe infections after burn injury: a clinical study. Shock Augusta Ga. 2015; 43: 222-7. https://doi.org/10.1097/SHK.0000000000000294.

[38] Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010; 37: 2369-76. https://doi.org/10.3899/jrheum.100247.

[39] Tschoeke SK, Oberholzer A, Moldawer LL. Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med. 2006; 34: 1225-33. https://doi.org/10.1097/01.CCM.0000208356.05575.16.

[40] Coban YK, Aral M. Serum IL-18 is increased at early post-burn period in moderately burned patients. Mediat Inflamm. 2006; 2006: 16492. https://doi.org/10.1155/MI/2006/16492.

[41] Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000; 117: 1162-72. https://doi.org/10.1378/chest.117.4.1162.

[42] Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev. 2003; 55: 241-69. https://doi.org/10.1124/pr.55.2.4.

[43] Csontos C, Foldi V, Pálinkas L, Bogar L, Röth E, Weber G, et al. Time course of pro-and anti-inflammatory cytokine levels in patients with burns-prognostic value of interleukin-10. Burns J Int Soc Burn Inj. 2010; 36: 483-94. https://doi.org/10.1016/j.burns.2009.10.009.

[44] Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000; 181: 176-80. https://doi.org/10.1086/315214.

[45] Tsurumi A, Que Y-A, Ryan CM, Tompkins RG, Rahme LG. TNF-α/IL-10 ratio correlates with burn severity and may serve as a risk predictor of increased susceptibility to infections. Front Public Health. 2016; 4: 216. https://doi.org/10.3389/fpubh.2016.00216.

[46] Zhang J, Hu Z-D, Song J, Shao J. Diagnostic value of Presepsin for sepsis: a systematic review and meta-analysis. Medicine (Baltimore). 2015; 94: e2158. https://doi.org/10.1097/MD.0000000000002158.

[47] Yaegashi Y, Sato N, Suzuki Y, Kojika M, Imai S, Takahashi G, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005; 11: 234-8. https://doi.org/10.1007/s10156-005-0400-4.

[48] Zou Q, Wen W, Zhang X. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014; 5: 16-9. https://doi.org/10.5847/wjem.j.issn.1920-8642.2014.01.002.

[49] Cakır Madenci Ö, Yakupo˘glu S, Benzonana N, Yücel N, Akbaba D, Orçun KA. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns J Int Soc Burn Inj. 2014; 40: 664-9. https://doi.org/10.1016/j.burns.2013.08.024.

[50] Wu J, Hu L, Zhang G, Wu F, He T. Accuracy of Presepsin in sepsis diagnosis: a systematic review and meta-analysis. Groeneveld ABJ, editor. PLoS One. 2015; 10: e0133057.

[51] Zhang S, Luan X, Zhang W, Jin Z. Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio as predictive biomarkers for early-onset neonatal sepsis. J Coll Physicians Surg-Pak JCPSP. 2021; 31: 821-4.

[52] Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: which ratio to choose to predict outcome and nature of Bacteremia? Mediat Inflamm. 2018; 2018: 1-15. https://doi.org/10.1155/2018/3758068.

[53] Kim M, Kym D, Park J, Yoon J, Cho YS, Hur J, et al. Big data insights into the diagnostic values of CBC parameters for sepsis and septic shock in burn patients: a retrospective study. Sci Rep. 2024; 14: 800. https://doi.org/10.1038/s41598-023-50695-z.

[54] Lin W-C, Chen C-W, Chao L, Chao J, Lin Y-S. Plasma kallistatin in critically ill patients with severe sepsis and septic shock. PLoS One. 2017; 12: e0178387. https://doi.org/10.1371/journal.pone.0178387.

[55] Dai Y, Zhao X. Therapeutic effects of simvastatin combined with kallistatin treatment for pediatric burn patients with sepsis. Exp Ther Med. 2018; 15: 3080-7. https://doi.org/10.3892/etm.2018.5791.

[56] Gao R-Y, Jia H-M, Han Y-Z, Qian B-S, You P, Zhang X-K, et al. Calprotectin as a diagnostic marker for sepsis: a meta-analysis. Front Cell Infect Microbiol. 2022; 12: 1045636. https://doi.org/10.3389/fcimb.2022.1045636.

[57] Larsson A, Tydén J, Johansson J, Lipcsey M, Bergquist M, Kultima K, et al. Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients. Scand J Clin Lab Invest. 2020; 80: 156-61. https://doi.org/10.1080/00365513.2019.1703216.

[58] Accardo Palumbo A, Forte GI, Pileri D, Vaccarino L, Conte F, D’Amelio L, et al. Analysis of IL-6, IL-10 and IL-17 genetic polymorphisms as risk factors for sepsis development in burned patients. Burns J Int Soc Burn Inj. 2012; 38: 208-13. https://doi.org/10.1016/j.burns.2011.07.022.

[59] Chi YF, Chai JK, Yu YM, Luo HM, Zhang QX, Feng R. Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients. Genet Mol Res GMR. 2015; 14: 10081-6. https://doi.org/10.4238/2015.August.21.15.

[60] Barber RC, Aragaki CC, Rivera-Chavez FA, Purdue GF, Hunt JL, Horton JW. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet. 2004; 41: 808-13. https://doi.org/10.1136/jmg.2004.021600.

[61] Sutherland A, Thomas M, Brandon RA, Brandon RB, Lipman J, Tang B, et al. Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care Lond Engl. 2011; 15: R149. https://doi.org/10.1186/cc10274.

[62] Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet. 2008; 9: 831-42. https://doi.org/10.1038/nrg2455.

[63] Correia CN, Nalpas NC, McLoughlin KE, Browne JA, Gordon SV, MacHugh DE, et al. Circulating microRNAs as potential biomarkers of infectious disease. Front Immunol. 2017; 8: 118. https://doi.org/10.3389/fimmu.2017.00118.

[64] Reithmair M, Buschmann D, Märte M, Kirchner B, Hagl D, Kaufmann I, et al. Cellular and extracellular miRNAs are blood-compartment-specific diagnostic targets in sepsis. J Cell Mol Med. 2017; 21: 2403-11. https://doi.org/10.1111/jcmm.13162.

[65] Yao L, Liu Z, Zhu J, Li B, Chai C, Tian Y. Clinical evaluation of circulating microRNA-25 level change in sepsis and its potential relationship with oxidative stress. Int J Clin Exp Pathol. 2015; 8: 7675-84.

[66] Guo H, Tang L, Xu J, Lin C, Ling X, Lu C, et al. MicroRNA-495 serves as a diagnostic biomarker in patients with sepsis and regulates sepsis-induced inflammation and cardiac dysfunction. Eur J Med Res. 2019; 24: 37. https://doi.org/10.1186/s40001-019-0396-3.

[67] Sun L, Li L, Yan J. Progress in relationship of the long non-coding RNA and sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017; 29: 181-3.

[68] Ng WL, Marinov GK, Liau ES, Lam YL, Lim Y-Y, Ea C-K. Inducible RasGEF1B circular RNA is a positive regulator of ICAM-1 in the TLR4/LPS pathway. RNA Biol. 2016; 13: 861-71. https://doi.org/10.1080/15476286.2016.1207036.

[69] Binnie A, Tsang JLY, Hu P, Carrasqueiro G, Castelo-Branco P, Dos Santos CC. Epigenetics of sepsis. Crit Care Med. 2020; 48: 745-56. https://doi.org/10.1097/CCM.0000000000004247.

[70] Dhas DBB, Ashmi AH, Bhat BV, Kalaivani S, Parija SC. Comparison of genomic DNA methylation pattern among septic and non-septic newborns-an epigenome wide association study. Genomics Data. 2015; 3: 36-40. https://doi.org/10.1016/j.gdata.2014.11.004.

[71] Steletou E, Metallinou D, Margeli A, Giannouchos T, Michos A, Kanaka-Gantenbein C, et al. Serum YKL-40 as a potential biomarker for sepsis in term neonates-a pilot study. Child Basel Switz. 2023; 10: 772. https://doi.org/10.3390/children10050772.

[72] Garcia-Obregon S, Azkargorta M, Seijas I, Pilar-Orive J, Borrego F, Elortza F, et al. Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. J Microbiol Immunol Infect. 2018; 51: 465-72. https://doi.org/10.1016/j.jmii.2016.12.002.

[73] Mert S, Bulutoglu B, Chu C, Dylewski M, Lin FM, Yu Y-M, et al. Multiorgan metabolomics and Lipidomics provide new insights into fat infiltration in the liver, muscle wasting, and liver-muscle crosstalk following burn injury. J Burn Care Res. 2021; 42: 269-87. https://doi.org/10.1093/jbcr/iraa145.

[74] Weber B, Henrich D, Hildebrand F, Marzi I, Leppik L. The ROLES of extracellular vesicles IN sepsis and systemic inflammatory response syndrome. Shock Augusta Ga. 2023; 59: 161-72. https://doi.org/10.1097/SHK.0000000000002010.

[75] Karasu E, Eisenhardt SU, Harant J, Huber-Lang M. Extracellular vesicles: packages sent with complement. Front Immunol. 2018; 9: 721. https://doi.org/10.3389/fimmu.2018.00721.

[76] Eguchi A, Kostallari E, Feldstein AE, Shah VH. Extracellular vesicles,the liquid biopsy of the future. J Hepatol. 2019; 70: 1292-4. https://doi.org/10.1016/j.jhep.2019.01.030.

[77] Fendl B, Weiss R, Eichhorn T, Linsberger I, Afonyushkin T, Puhm F, et al. Extracellular vesicles are associated with C-reactive protein in sepsis. Sci Rep. 2021; 11: 6996. https://doi.org/10.1038/s41598-021-86489-4.

[78] Tian C, Liu J, Di X, Cong S, Zhao M, Wang K. Exosomal hsa_circRNA_104484 and hsa_circRNA_104670 may serve as potential novel biomarkers and therapeutic targets for sepsis. Sci Rep. 2021; 11: 14141. https://doi.org/10.1038/s41598-021-93246-0.

[79] Yang X, Chatterjee V, Zheng E, Reynolds A, Ma Y, Villalba N, et al. Burn injury-induced extracellular vesicle production and characteristics. Shock. 2022; 57: 228-42. https://doi.org/10.1097/SHK.0000000000001938.

[80] O’Toole HJ, Lowe N, Arun V, Kolesov AV, Palmieri TL, Tran NK. et al. Plasma-derived extracellular vesicles (EVs) as biomarkers of sepsis in burn patients via label-free Raman spectroscopy [internet]. J Extracell Vesicles. 2024; 13: e12506. [cited 2024 Sep 18]. Available from: http://biorxiv.org/lookup/doi/10.1101/2024.05.14.593634.

[81] Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019; 321: 2003-17. https://doi.org/10.1001/jama.2019.5791.